BOUNDLESS BIO, INC. Operating Lease Cost
BOUNDLESS BIO, INC. (BOLD) reported Operating Lease Cost of $6.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-07
- BOUNDLESS BIO, INC. operating lease, cost for the quarter ending 2026-06-30 was $6.20M, a 244.44% increase year-over-year.
- BOUNDLESS BIO, INC. operating lease, cost for the quarter ending 2025-06-30 was $1.80M.
- BOUNDLESS BIO, INC. operating lease, cost for fiscal 2024 was $3.60M, a 38.46% increase from fiscal 2023.
- BOUNDLESS BIO, INC. operating lease, cost for fiscal 2023 was $2.60M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 12 month |
|---|---|---|---|
| 2026-06-30 | $6.20M 10-Q · filed 2026-08-07 | $8.10M 10-Q · filed 2026-08-07 | |
| 2025-06-30 | $1.80M 10-Q · filed 2026-08-07 | $3.70M 10-Q · filed 2026-08-07 | |
| 2024-12-31 | $3.60M 10-K · filed 2025-03-27 | ||
| 2023-12-31 | $2.60M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |